anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rheumatoid arthritis (RA) is a chronic and disabling disease. TNF-α inhibitors have demonstrated an outstanding performance in relieving joint inflammation and retarding bone erosion involved in RA. However, there is still about one-thirds of RA patients had a poor response to TNF α inhibitors. Currently the personalized biological treatment is the research hotspot. Recent studies focuses on exploring biomarkers predictive of drug response. The research methods such as genomics, transcriptomics, proteomics, metabolomics and immunocytology, have been applied,but they are not successfully integrated. The related studies in China are still at an initial stage, which necessitates an in-depth study in this area. The investigators' preliminary study showed that TNF-α-308 gene polymorphisms existed in Chinese RA patients and phosphoinositide 3-kinase/Akt signal pathway was activated in proliferated synovial fibroblasts stimulated by TNF-α. Therefore, for the first attempt in China, the investigators intend to screen for differential proteins by using isobaric tags for relative and absolute quantitation(iTRAQ) technique in RA patients receiving anti-TNF-α therapy, and then verify the predictive effects of selected differential proteins from the upstream gene polymorphism to the downstream protein expression. The investigators will also explore the mechanisms of differential proteins involved in TNF-α related signal pathway by using in vitro gene transfer, siRNA interference, and RA animal models. Through this study investigator hope to discover some prediction proteins with a domestic genetic background and finally establish a prediction system with Chinese characteristics.
Haloperidol decanoate is the decanoate ester of the butyrophenone, haloperidol decanoate injection. It has a markedly extended duration of effect. It is available in sesame oil in sterile form for intramuscular (IM) injection. The structural formula of haloperidol decanoate, 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4 piperidinyl decanoate, is: 

Haloperidol decanoate, USP is a white or almost white powder. It very soluble in alcohol, in methanol and in methylene chloride, practically insoluble in water.

Haloperidol decanoate injection is clear, slightly viscous, colorless to pink or amber solution.

Each mL of haloperidol decanoate injection for intramuscular injection contains 50 mg haloperidol (present as haloperidol decanoate, USP 70.52 mg) in a sesame oil vehicle, with 1.2% (w/v) benzyl alcohol as a preservative. 

Each mL of haloperidol decanoate injection for intramuscular injection contains 100 mg haloperidol (present as haloperidol decanoate, USP 141.04 mg) in a sesame oil vehicle, with 1.2% (w/v) benzyl alcohol as a preservative.
Visual impairment due to ophthalmological diseases significantly affects functional activity in everyday life, since good eyesight is crucial in daily activities. Data from 837 respondents were studied, allowing for analysis of such medical and demographic indicators as age, gender, level of education, visual acuity arterial hypertension and diabetes mellitus. To measure functional status, the main activities in daily life (ADL) and instrumental activities in daily life (IADL) were evaluated using a modified version of the Katz scale and the IADL OARS scale. Statistical methods of Mantel-Hansel Chi-squared analysis were used to assess differences in the prevalence of functional blindness and visual deficit. The study showed that medical and demographic factors have a relatively smaller impact on vision deficiency compared to functional blindness, with age being a significant factor in both cases. Among the medical and demographic factors, the age of patients, as well as diabetes mellitus, significantly increase the development of visual deficiency and functional blindness. Functional blindness, in comparison with visual deficiency, causes more significant restrictions on activities in everyday life and instrumental activities in everyday life, and also causes dependence on help from others.
Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
A clinical dashboard device, system, method for providing clinical data for clinical dashboard display on a device is disclosed. The system includes a server for providing clinical dashboard data, which may include data from one or more defibrillators, and further includes a clinical dashboard device. The clinical dashboard device includes a processor, a communication module configured for enabling communication between the processor and the server for receiving the clinical dashboard data from the server, and a clinical dashboard client. The clinical dashboard client includes a clinical dashboard data manager module including an instance of a clinical dashboard data manager service that provides managed clinical dashboard data between one or more clinical dashboard applications and the server. The instance of the clinical dashboard data manager service further provides managed display of managed clinical dashboard data on the display of the clinical dashboard device. The processor is configured to execute the instance.
Hypothalamic obesity (HO) is a rare and complex disorder that confers substantial morbidity and excess mortality. HO is a unique subtype of obesity characterized by impairment in the key brain pathways that regulate energy intake and expenditure, autonomic nervous system function, and peripheral hormonal signalling. HO often occurs in the context of hypothalamic syndrome, a constellation of symptoms that follow from disruption of hypothalamic functions, for example, temperature regulation, sleep-wake circadian control, and energy balance. Genetic forms of HO, including the monogenic obesity syndromes, often impact central leptin-melanocortin pathways. Acquired forms of HO occur as a result of tumours impacting the hypothalamus, such as craniopharyngioma, surgery or radiation to treat those tumours, or other forms of hypothalamic damage, such as brain injury impacting the region. Risk for severe obesity following hypothalamic injury is increased with larger extent of hypothalamic damage or lesions that contain the medial and posterior hypothalamic nuclei that support melanocortin signalling pathways. Structural damage in these hypothalamic nuclei often leads to hyperphagia, central insulin and leptin resistance, decreased sympathetic activity, low energy expenditure, and increased energy storage in adipose tissue, the collective effect of which is rapid weight gain. Individuals with hyperphagia are perpetually hungry. They do not experience fullness at the end of a meal, nor do they feel satiated after meals, leading them to consume larger and more frequent meals. To date, most efforts to treat HO have been disappointing and met with limited, if any, long-term success. However, new treatments based on the distinct pathophysiology of disturbed energy homeostasis in acquired HO may hold promise for the future.
This study is a consecutive cohort study. Subjects will be recruited from Urogynaecology clinics at Medway NHS Foundation Trust. Patients will be identified from previous records and also prospectively from new patients. They will be sent information regarding the trial before attending their first appointment.

Patients attending urogynaecology clinics will provide a fresh clean catch specimen of urine. A conventional hospital Mid stream speciemn of urine (MSU) will be sent. Urine will be dipsticked for nitrites and leucocyte esterase. The urine will then be spun and undergo microscopy using a special stain (looking for intracellular organisms in shed urothelial cells). The urothelial cells will be cleaned with antibiotics. The cells will then be lysed and their contents cultured. The contents will undergo Polymerase Chain Reaction (PCR) sequencing to identify bacteria. Sensitivity testing will be used to assess and deliver the appropriate antibiotic regime.

Women will be treated with a 6 week course of antibiotics as per their usual treatment. Broad spectrum antibiotics will be prescribed to all women based on the previous successful therapeutic regime as described by Vijaya. Six weeks after the end of antibiotic therapy patients will be reviewed and their urine retested.
The present invention relates to the development of novel compounds of chromeno [4,3-b] quinolone derivatives. It particularly relates to the development of novel compounds of thiochromeno [4,3-b] quinolone derivatives for the treatment of coronary artery diseases, dyslipidemia, and metabolic syndrome. The present invention also relates to the first synthesis of Silicotungstic -catalyzed Aza-Diels-Alder-reactions (ADAR) with s-prenyl derivatives of α-tetralone, 4-chromanone and Thiochroman-4-one and various substituted amines to deliver cycloadducts in good yield and excellent diastereoselectivity under mild reaction conditions. The invention further relates to the method for the treatment of coronary artery diseases, dyslipidemia, and metabolic syndrome by using synthesized compounds of thiochromeno [4,3-b] quinolone derivatives. The present invention provides the use of Silicotungstic acid as Lewis acid for Aza-Diels-Alder-reactions to get a mixture of diastereomers are the first examples. In addition to its efficiency, simplicity, and mild reaction conditions, the catalyst is very cheap and only a small amount (10 mol%) is needed. Intramolecular cyclization was carried out very conveniently as a one-pot reaction starting from the S-prenyl chromene-3-carbaldehyde and arylamines without isolation of the intermediate imines.
This pilot study is designed to evaluate the diagnostic ability of a novel APD for auricular point detection among patients with menstrual migraine (MMG), as compared with an already commercialized device. The investigators will test if the novel APD could provide a more reliable and quantifiable diagnosis of MMG-related auricular point than traditional devices currently available in the market; The study will also use the APD device to test whether the cutaneous electrical impedance detected from the corresponding auricular points by the novel device is the lowest in the reproductive organ and facial area in the MMG population. As a pilot study, 12 patients with MMG will be recruited from the School of Chinese Medicine, the University of Hong Kong. 12 healthy subjects will be recruited from the university community. Auricular acupoint detection will be accomplished with the new device and a control device. The electrical impedance will be measured and recorded. Patient's condition will also be evaluated by the visual analogue scale (VAS) and the Modified New England Center of Headache (NECH) headache calendar. The specificity and sensitivity of the auricular point detection by the APD device will be calculated. Cohen's kappa coefficient (κ) will be used to test the inter-methods reliability, test-retest reliability, and inter-tester reliability. Moreover, the Pearson Correlation Coefficient will be used to test the correlation between the electrical impedance of the auricular point and the pain intensity score.
PROBLEM TO BE SOLVED: To obtain a composition for hair, comprising carpronium chloride, pantothenyl ethyl ether and a water-soluble chitin derivative, reduced in stickiness after use and capable of raising the stability of carpronium chloride to water. SOLUTION: This composition coptaining carpronium chloride comprises the carpronium chloride having local vasodilator actions and pantothenyl ethyl ether and a water-soluble chitin derivative having stabilizing actions on the carpronium chloride and hair root activating actions (e.g. hydroxypropyl chitosan). Furthermore, one more crude drugs having hair growth, trichogenous or hair tonic effects (e.g. Polygoni multiflori Radix or Panacis japonici Rhizoma) are contained therein. The carpronium chloride is used in an amount of 0.1-10wt.% and other ingredients are blended in the following amounts based on 1 pt.wt. carpronium chloride: (1/20) to 20 pts.wt. pantothenyl ethyl ether, (1/100) to (1/5) pt.wt. water-soluble chitin derivative and (1/5) to 20 pts.wt. crude drugs.  The composition is the one for hair growth, trichogenous and hair tonic use and effective against alopecia, dandruff, pruritus, hair production insufficiency, baldness, etc.
Gestational diabetes mellitus (GDM) defined as glucose intolerance first detected during pregnancy is a strong predictor of future type 2 diabetes. Patients with GDM exhibit severely reduced postprandial responses of the insulinotropic and satiety-promoting gut hormone glucagon-like peptide 1 (GLP-1), which normalise alongside remission of GDM after delivery. Ingested nutrients and bile acids constitute potent stimulators of GLP-1 secretion. Reduced postprandial GLP-1 responses likely contribute to the pathophysiology of GDM, but the mechanisms are unknown. Based on previous studies studying gallbladder emptying during pregnancy, we hypothesize that reduced postprandial GLP-1 responses in GDM is due to incomplete gallbladder emptying during third trimester. If our hypothesis proves right, reduced gallbladder emptying and ensuing attenuation of postprandial GLP-1 secretion will constitute an obvious and druggable target for the treatment of GDM.

Fifteen women with gestational diabetes mellitus and 15 age and body mass index (BMI)-matched pregnant women with normal glucose tolerance will be enrolled in the study. For each subject, the study encompasses one screening visit and two experimental days; one during third trimester of pregnancy and one 3-9 months post partum. On experimental days, a standardised liquid mixed meal test (added 1.5 g of paracetamol for evaluation of gastric emptying according to paracetamol absorption) with repeated ultrasonographic gallbladder scans and blood samples will be performed.
<P>PROBLEM TO BE SOLVED: To provide an emulsifier dispersion which can give additional values to shampoos, rinses or other liquid cleansers, and to provide a method for producing the emulsifier dispersion.  <P>SOLUTION: This method for producing the emulsifier dispersion, comprising mixing a fatty acid glycol ester with a surfactant-containing component containing at least one surfactant selected from a nonionic surfactant, an anionic surfactant and an amphoteric surfactant at a higher temperature than the melting point of the fatty acid glycol ester, and then mixing the mixture with a cooling medium to cool the mixture, is characterized by the following characteristics. The mass ratio of the amount (solid content) of at least one surfactant selected from the anionic surfactant and the amphoteric surfactant to the amount of the fatty acid glycol ester is 0.1 to 5. The mass ratio of the amount (solid content) of the nonionic surfactant to the amount of the fatty acid glycol ester is 0 to 0.24. When the mixture is mixed with the cooling medium to directly cool the mixture, a cooling rate is ≥1°C/min at temperatures near to the melting point of the fatty acid glycol ester.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
OBJECTIVE: Tracheal collapse (TC) is an obstructive respiratory disorder in dogs that can affect lifespan and quality of life. Systemic inflammation has been identified in other obstructive airway conditions in dogs and humans. We hypothesized a systemic pro-inflammatory state exists in dogs with TC.
ANIMALS: Dogs with TC (TC, n = 15) and healthy, non-affected controls (C, n = 15), were prospectively enrolled.
PROCEDURE: Signalment and body condition score (BCS) were recorded for all dogs. For TC dogs, cough duration, pharyngeal collapse, bronchial collapse, and previous stent placement were recorded. Plasma samples were banked at -80°C and batch-analyzed for interleukin-8 (IL-8). Differences between groups were evaluated.
RESULTS: Yorkshire terriers were overrepresented in the TC group. The TC group was older than the C group and had a higher BCS. Interleukin-8 was significantly greater in the TC compared to the C group. Interleukin-8 was not correlated with age sex, BCS, breed, cough duration, pharyngeal collapse, bronchial collapse, or stent placement.
CONCLUSION AND CLINICAL RELEVANCE: Increased plasma IL-8 concentration supports the presence of systemic inflammation in canine TC. Dogs with TC were older than controls, with a higher BCS, but this did not account for the increased IL-8. Further investigation of IL-8 as a potential biomarker for monitoring TC progression and therapeutic response is warranted.
A biological pacemaker and implantation catheter for restoring normal or near normal heartbeat function without a mechanical pacemaker. The biological pacemaker is provided by a bridge of implantation cells, such as nerve cells, stem cells or ganglion cells, that are introduced into an area of electrical malfunction, such as an impaired SA node or a blocked AV node. The implantation cells grow to form a conductive cell bridge around the malfunction area so that a new pathway is provided for the electrical signals responsible for triggering heart beat contractions. The implantation catheter has a central nerve cell injection needle connected to a syringe or the like via a cell injection tube, and two elongated lateral stabilizing needles. The catheter is inserted into a blood vessel in a patient's leg, arm, shoulder or the like, and advanced until the catheter's distal end is located above the malfunction area. The distal end of the catheter is bent so that the three needles are facing the malfunction area. The two stabilizing needles are advanced into the heart wall to stabilize the catheter and the nerve cell injection needle is advanced for injection of the implantation cells.
Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression among adult. The approved method for treatment is 10Hz stimulation over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been successful for many people with treatment-resistant depression. However, a large percentage of adolescents suffering from major depressive disorder (MDD) do not adequately benefit from currently available treatments. One of the limitations is concerns about the safety and efficacy of antidepressant. Recently, researchers have aggressively pursued better treatment strategy such as rTMS to improve adolescent depression with some preliminary success. This study intends to further explore the safety and efficacy of rTMS in the treatment for adolescent major depressive disorder with anhedonia. This study will also look at the change in neuroimaging biomarkers associated with this treatment.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of halobetasol propionate.

In a 90-day repeat-dose toxicity study in rats, topical administration of Halobetasol Propionate Topical Foam at dose concentrations from 0.005% to 0.05% or from 0.011 to 0.11 mg/kg/day of halobetasol propionate resulted in a toxicity profile consistent with long-term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression, and opportunistic fungal and bacterial infections. A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk of carcinogenesis.

Halobetasol propionate was not found to be genotoxic in the Ames/Salmonella assay, in the Chinese hamster CHO/HGPRT assay, in the mouse micronucleus test, in the sister chromatid exchange test in somatic cells of the Chinese hamster, or in the chromosome aberration test in somatic cells of Chinese hamsters. Positive mutagenicity effects were observed in two genotoxicity assays: Chinese hamster nuclear anomaly test and mouse lymphoma gene mutation assay in vitro.

Studies in the rat following oral administration at dose levels up to 0.05 mg/kg/day indicated no impairment of fertility or general reproductive performance.
The present invention relates to oral liquid for replenishing vital essence, removing dryness and reducing glucose and a preparation method thereof. The oral liquid is a pure Chinese medicine preparation decocted with water, for treating II-type diabetes. The oral liquid is prepared from milkvetch root, common yam rhizome, prepared rhizome of rehmannia, rehmannia root, kudzuvine root, solomonseal rhizome, figwort root, barbary wolfberry fruit, golden thread, Chinese Wolfberry Root-bark, danshen root, cowherb seed, white peony alba, pulp of dogwood fruit, atractylodes, dodder seed, epimedium herb, lychee seed, excrementum bombycis, etc. The liquid is extracted after the Chinese drugs are decocted with water, and the liquid is condensed by reducing pressure and is filled into germ free bottles to be hermetically stored. The content of the decocted liquid in each bottle is 10 milliliters. The oral liquid takes the uses of clearing heat and promoting fluid, supplementing qi and nourishing yin and rectifying disturbance of carbohydrate metabolism as the basic principle of treatment. After the oral liquid is admitted for 20 days to 2 mouths, the symptoms can be eased, the weight can be gained, the oomph goes better and the blood sugar index reaches the normal range until the II-type diabetes is cured. The oral liquid has no abuses of drug resistance or drug dependence or toxic or side effect.
1,209,093. Sustained release compositions containing lithium salts. DELANDALE LABORATORIES Ltd. 9 July, 1969 [16 July, 1968], No. 33845/68. Heading A5B.  Sustained release pharmaceutical compositions for the treatment of manic depressive states comprise (i) a powdered therapeutically active lithium salt such as lithium carbonate, (ii) a sustained release agent comprising a mixture of glyceryl mono-, di- and tri-esters of one or more C 16-18  straight chain saturated fatty acids e.g. palmitic and stearic acids, and (iii) other innocuous compounding materials. The composition may be in the form of a tablet comprising a filler e.g. mannitol, a binding agent e.g. gum acacia and a lubricant e.g. magnesium stearate. Tablets may be prepared by (1) mixing a dry powdered lithium salt and a dry powdered filler, (2) mixing therewith a solution of the sustained release agent, (3) adding a solution of a binding agent and kneading the mixture, (4) drying and granulating the resulting mass and optionally adding a lubricant to the granules and (5) compressing into tablets 51 to 61 parts by weight of ingredient (ii) may be present per 100 parts by weight of ingredient (i). Preferably the sustained release agent is added in alcohol solution and at 68‹C or more, the powdered lithium salt and filler being pre-heated to about this temperature before adding the solution at step (2).
The invention relates to the field of daily necessities, in particular to faintly acid essential oil hairdressing soap and a manufacturing method thereof. The faintly acid essential oil hairdressing soap comprises five-cereal powder, fruit powder, apple amino acid, coco glucoside sodium hydroxyethyl sulfonate SCI-75, ethylhexyl olivate, glycerol, essential oil, coloring matter, essence and the balanced water. The coco glucoside sodium hydroxyethyl sulfonate SCI-75, the ethylhexyl olivate and the glycerol serve as basic formulas of the faintly acid essential oil hairdressing soap so as to be safe and stable. Essential oil is added, and the mood and the physiological function of the body are adjusted through the cortex. The five-cereal powder and the fruit powder serve as materials and are natural and free of pollution; chemical stimulations are reduced; in addition, the fruit powder has fruity odors and brings the odors to a user. According to the market requirement, the essence and the coloring matter can be added, and the kinds of products are enriched.